Morphogenesis of Marandu Brachiaria Under Different Nitrogen Rates in the Brazilian Savannah

Nitrogen fertilization contributes to grass growth and, for this reason, the objective was to evaluate the morphogenic characteristics of Urochloa brizantha cultivar Marandu subjected to different nitrogen rates (0, 50, 100 and 150 kg N.ha-1) in the Brazilian savannah through the variables number of leaves.tiller-1, leaf growth, leaf average size, senescent leaf.tiller-1 number and stem+pseudostem average size. The experiment was established in the Forage and Pastures Sector of Jatai Federal University (UFJ) and, after the soil correction and fertilization, the Marandu grass plots were installed in a randomized blocks experimental design, with four treatments and four replications. When the forage canopy reached the cutting height (30 cm) it was homogenized with pruning shears and four tillers per plot were identified with colored tape and a locating stake. Morphogenesis data was collected every two days, measuring the leaves size and stem+pseudostem size, and leaves were classifying according to their physiological state. Marandu cultivar showed increasing response in leaves number and in leaf growth in nitrogen doses from 50 to 100 kg N.ha-1. The number of senescent leaf.tiller-1 decrease when nitrogen fertilization increase from 0 to 100 kg N.ha-1. Marandu showed a morphogenic response to nitrogen fertilization and up to 100 kg N.ha-1 can be used

Brownian motion exhibiting absolute negative mobility

We consider a single Brownian particle in a spatially symmetric, periodic system far from thermal equilibrium. This setup can be readily realized experimentally. Upon application of an external static force F, the average particle velocity is negative for F>0 and positive for F<0 (absolute negative mobility).Comment: 4 pages, 3 figures, to be published in PR

Observation of negative absolute resistance in a Josephson junction

We experimentally demonstrate the occurrence of negative absolute resistance (NAR) up to about $-1\Omega$ in response to an externally applied dc current for a shunted Nb-Al/AlO$_x$-Nb Josephson junction, exposed to a microwave current at frequencies in the GHz range. The realization (or not) of NAR depends crucially on the amplitude of the applied microwave current. Theoretically, the system is described by means of the resistively and capacitively shunted junction model in terms of a moderately damped, classical Brownian particle dynamics in a one-dimensional potential. We find excellent agreement of the experimental results with numerical simulations of the model.Comment: 4 pages, 3 figures, submitted to Physical Revie

DAMPAK BERMAIN GAME ONLINE DALAM MEMPERLUAS RELASI SOSIAL PADA PEMAIN GAME ONLINE DOTA 2

This research was conducted in order to find out the impact in social relations in DOTA online game players. The method used in this research is qualitative research methods using a phenomenological approach, namely research taken based on phenomena that exist in society. The researcher used interviews and observation as a method of retrieving data. The subjects of this study were 3 students of Soegijapranata Catholic University Semarang, playing online game Dota 2 and able to communicate well. The data analysis method that the researcher uses is inductive, which is an analysis of data based on the data that has been obtained, and then developed into general conclusions. The research results obtained, namely playing online games can have a positive impact on social relations such as expanding the social relations of the players. In addition, researchers also found that there was a negative impact from playing online games on social relations in the parent subject, namely the time to communicate was reduced. Keywords: online games, social relations, the impact of playing online games

Update breast cancer 2022 part 4 – advanced-stage breast cancer

For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for overall survival. This review summarizes the latest results, which have been published at current congresses or in specialist journals, and classifies them in the clinical treatment context. In particular, the importance of therapy with CDK4/6 inhibitors – trastuzumab deruxtecan, sacituzumab govitecan and capivasertib – is discussed. For trastuzumab deruxtecan, an overall survival benefit in HER2-negative breast cancer with low HER2 expression (HER2-low expression) was reported in the Destiny-Breast-04 study. Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. The lack of overall survival benefit for palbociclib in the first line of therapy raises the question of clinical classification

Update Breast Cancer 2022 part 3 – Early-stage breast cancer

This review summarizes recent developments in the prevention and treatment of patients with early-stage breast cancer. The individual disease risk for different molecular subtypes was investigated in a large epidemiological study. With regard to treatment, new data are available from long-term follow-up of the Aphinity study, as well as new data on neoadjuvant therapy with atezolizumab in HER2-positive patients. Biomarkers, such as residual cancer burden, were investigated in the context of pembrolizumab therapy. A Genomic Grade Index study in elderly patients is one of a group of studies investigating the use of modern multigene tests to identify patients with an excellent prognosis in whom chemotherapy may be avoided. These and other aspects of the latest developments in the diagnosis and treatment of breast cancer are described in this review

Update breast cancer 2022 part 2 – advanced stage breast cancer

For patients with advanced breast cancer, several novel therapies have emerged in recent years, including CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, alpelisib, tucatinib and trastuzumab-deruxtecan, and sacituzumab-govitecan, which have transformed and expanded the therapeutic landscape for patients with advanced breast cancer. Some of these substances have now been approved for use in the early stages of the disease, or are expected to be approved in the near future, so the therapeutic landscape will change once again. Therefore, current scientific efforts are focused on the introduction of new substances and understanding their mechanisms of progression and efficacy. This review summarizes recent developments with reference to recent publications and conferences. Findings on the treatment of patients with HER2-positive breast cancer and brain metastases are presented, as are a number of studies looking at biomarkers in patients with HER2-negative, hormone receptor-positive breast cancer. In particular, the introduction of oral selective estrogen receptor degraders provides new opportunities to establish biomarker-based therapy. Molecular diagnostics is establishing itself as a diagnostic marker and parameter of progression

Update breast cancer 2022 part 1 – early stage breast cancer

Evidence relating to the treatment of breast cancer patients with early-stage disease has increased significantly in the past year. Abemaciclib, olaparib, and pembrolizumab are new drugs with good efficacy in the relevant patient groups. However, some questions remain unanswered. In particular, it remains unclear which premenopausal patients with hormone receptor-positive breast cancer should be spared unnecessary treatment. The question of the degree to which chemotherapy exerts a direct cytotoxic effect on the tumor or reduces ovarian function through chemotherapy could be of key importance. This group of patients could potentially be spared chemotherapy. New, previously experimental biomarker analysis methods, such as spatial analysis of gene expression (spatial transcriptomics) are gradually finding their way into large randomized phase III trials, such as the NeoTRIP trial. This in turn leads to a better understanding of the predictive factors of new therapies, for example immunotherapy. This review summarizes the scientific innovations from recent congresses such as the San Antonio Breast Cancer Symposium 2021 but also from recent publications

Vilnius Declaration on chronic respiratory diseases : multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases

Correction: Volume: 10 Issue: 1 Article Number: 49 DOI: 10.1186/s13601-020-00357-4 Published: DEC 17 2020Background: Over 1 billion people suffer from chronic respiratory diseases such as asthma, COPD, rhinitis and rhinosinusitis. They cause an enormous burden and are considered as major non-communicable diseases. Many patients are still uncontrolled and the cost of inaction is unacceptable. A meeting was held in Vilnius, Lithuania (March 23, 2018) under the patronage of the Ministry of Health and several scientific societies to propose multisectoral care pathways embedding guided self-management, mHealth and air pollution in selected chronic respiratory diseases (rhinitis, chronic rhinosinusitis, asthma and COPD). The meeting resulted in the Vilnius Declaration that was developed by the participants of the EU Summit on chronic respiratory diseases under the leadership of Euforea. Conclusion: The Vilnius Declaration represents an important step for the fight against air pollution in chronic respiratory diseases globally and has a clear strategic relevance with regard to the EU Health Strategy as it will bring added value to the existing public health knowledge.Peer reviewe